|
gptkbp:instance_of
|
gptkb:biotechnology
gptkb:Company
|
|
gptkbp:acquired
|
gptkb:Civitas_Therapeutics
rights to Inbrija
|
|
gptkbp:acquisition
|
gptkb:Cortex_Pharmaceuticals
Neuroges X
|
|
gptkbp:ceo
|
gptkb:Ron_Cohen
|
|
gptkbp:clinical_trial
|
gptkb:neurodegenerative_diseases
gptkb:multiple_sclerosis
Phase 1
drug development
Phase 2
Phase 3
improving walking in multiple sclerosis patients
off-period symptoms in Parkinson's disease
|
|
gptkbp:collaboration
|
academic institutions
research organizations
|
|
gptkbp:focus
|
neurological diseases
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founded_in
|
gptkb:2004
|
|
gptkbp:founder
|
gptkb:Ron_Cohen
|
|
gptkbp:has_advisory_board
|
experts in neurology
|
|
gptkbp:headquarters
|
gptkb:Ardsley,_New_York
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Acorda Therapeutics
|
|
gptkbp:investment
|
$100 million
venture capital firms
|
|
gptkbp:market
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mission
|
improve the lives of people with neurological disorders
|
|
gptkbp:number_of_employees
|
approximately 200
|
|
gptkbp:partnership
|
gptkb:U._S._Food_and_Drug_Administration
biopharmaceutical companies
|
|
gptkbp:product
|
gptkb:Ampyra
gptkb:Inbrija
|
|
gptkbp:regulatory_compliance
|
FDA approval for Ampyra
FDA approval for Inbrija
|
|
gptkbp:research_areas
|
chronic pain
oral medication
spasticity
inhalation therapy
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
ACOR
|
|
gptkbp:vision
|
transforming the treatment of neurological diseases.
|
|
gptkbp:website
|
acorda.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|